Publications by authors named "Manasee V Shah"
Article Synopsis
- This study evaluated the preferences for treatment attributes of maintenance therapies in patients with acute myeloid leukemia (AML) following hematopoietic stem cell transplantation (HSCT) and compared these preferences to those of their treating physicians.* -
- A web-based discrete choice experiment was conducted involving 84 patients and 149 physicians across the US, UK, Canada, and Australia, focusing on six key treatment attributes such as quality of life (QoL) and risk of infections, to understand their impact on treatment choices.* -
- Results revealed that patients prioritized quality of life and duration of hospitalization, while physicians focused more on the chance of 2-year relapse-free survival, highlighting differing values that should inform patient-centered treatment decisions post-HS
The symptoms of acute myeloid leukemia (AML) and its treatment can negatively impact patient functioning and quality of life. Through concept elicitation interviews, we sought to evaluate the experience of patients with AML in remission following hematopoietic stem cell transplant (HSCT). Thirty patients with AML in remission post-HSCT, and eight clinicians with experience treating such patients, were asked to identify symptoms and impacts associated with AML and/or its treatment.
View Article and Find Full Text PDFPatient-reported outcomes (PROs) can inform treatment selection and assess treatment value in acute myeloid leukemia (AML). We evaluated PROs from the ADMIRAL trial (NCT02421939) in patients with -mutated relapsed/refractory (R/R) AML. PRO instruments consisted of Brief Fatigue Inventory (BFI), Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu), Functional Assessment of Chronic Illness Therapy-Dyspnea Short Form (FACIT-Dys SF), EuroQoL 5-Dimension 5-Level (EQ-5D-5L), and leukemia treatment-specific symptom questionnaires.
View Article and Find Full Text PDFCost-effectiveness of gilteritinib for relapsed/refractory acute myeloid leukemia.
J Manag Care Spec Pharm
October 2021
Patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) and confirmed feline McDonough sarcoma (FMS)-like tyrosine kinase 3 gene mutations () have a poor prognosis and limited effective treatment options. Gilteritinib is the first targeted therapy approved in the United States and Europe for R/R AML with significantly improved efficacy compared with existing treatments. To evaluate gilteritinib against salvage chemotherapy (SC) and best supportive care (BSC) over a lifetime horizon among adult patients with R/R AML from a US third-party payer's perspective.
View Article and Find Full Text PDFObjectives: Maintenance therapy is one strategy to prolong survival in patients with acute myeloid leukemia (AML) following hematopoietic stem cell transplantation (HSCT). We evaluated real-world treatment patterns and outcomes in patients with newly diagnosed FLT3-mutated AML receiving HSCT after complete remission with first-line chemotherapy.
Methods: A global, retrospective chart review to evaluate maintenance therapy and outcomes in patients with FLT3-mutated AML after HSCT.
Aims: To estimate the economic impact of the introduction of gilteritinib for the treatment of relapsed/refractory (R/R) mutation-positive ( ) acute myeloid leukemia (AML) from a US payer's perspective.
Methods: A budget impact model (BIM) was developed to evaluate the 3-year total budgetary impact of treating adults with R/R AML eligible for gilteritinib in a hypothetical US health plan. Total costs (drugs/administration, hospitalization, monitoring, adverse events, transfusions, subsequent hematopoietic stem cell transplantation, post-progression, and testing) were estimated before and after gilteritinib entry.
Article Synopsis
- The study aimed to evaluate treatment patterns and healthcare resource use among patients with FLT3-mutated and FLT3-wild-type acute myeloid leukemia (AML) across 10 countries.
- Data was collected from medical charts of 1027 AML patients, revealing diverse treatment approaches based on FLT3 mutation status, age, and disease stage (newly diagnosed or relapsed/refractory).
- Results showed that FLT3 AML patients received more aggressive treatment compared to FLT3 wild-type patients, with significant healthcare resource utilization noted, especially after relapse or treatment failure.
Introduction: To assess the impact on hospitalization costs of multimodal analgesia (MMA), including intravenous acetaminophen (IV-APAP), versus IV opioid monotherapy for postoperative pain management in patients undergoing orthopedic surgery.
Methods: Utilizing the Truven Health MarketScan Hospital Drug Database (HDD), patients undergoing total knee arthroplasty (TKA), total hip arthroplasty (THA), or surgical repair of hip fracture between 1/1/2011 and 8/31/2014 were separated into postoperative pain management groups: MMA with IV-APAP plus other IV analgesics (IV-APAP group) or an IV opioid monotherapy group. All patients could have received oral analgesics.
Objective: To determine the variable burden of disease of patients with advanced estrogen receptor-positive (ER+) breast cancer and assess the current treatment landscape after failure of first-line endocrine therapy.
Methods: A comprehensive literature review was performed (2000-2011) by searching Medline via PubMed, and Embase and Cochrane databases, to assess disease burden (i.e.